CD47-CAR-T Cells Effectively Kill Target Cancer Cells and Block Pancreatic Tumor Growth

FLAG-tagged CD19-specific CAR-T cells eliminate CD19-bearing solid tumor cells i in vitro i and i in vivo i

(2017) Vita M Golubovskaya   Frontiers in Bioscience-Landmark

Disrupting the CD47-SIRPα anti-phagocytic axis by a humanized anti-CD47 antibody is an efficacious treatment for malignant pediatric brain tumors

(2017) Sharareh Gholamin et al.   Science Translational Medicine

Regional Delivery of Chimeric Antigen Receptor (CAR) T-Cells for Cancer Therapy

(2017) et al.   Cancers

How One Thing Led to Another

(2016) Irving Weissman   Annual Review of Immunology

Therapeutic Potential of T Cell Chimeric Antigen Receptors (CARs) in Cancer Treatment: Counteracting Off-Tumor Toxicities for Safe CAR T Cell Therapy

(2016) Gideon Gross et al.   Annual Review of Pharmacology and Toxicology

Regional CAR-T cell infusions for peritoneal carcinomatosis are superior to systemic delivery

(2016) S C Katz et al.   CANCER GENE THERAPY

CD47: a potential immunotherapy target for eliminating cancer cells

(2016) F. Kong et al.   Clinical & Translational Oncology

The CD47 “don't eat me signal” is highly expressed in human ovarian cancer

(2016) R.M. Brightwell et al.   GYNECOLOGIC ONCOLOGY

CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer

(2016) Kipp Weiskopf et al.   JOURNAL OF CLINICAL INVESTIGATION

A fully human anti-CD47 blocking antibody with therapeutic potential for cancer

(2016) Dadi Zeng et al.   Oncotarget

A function-blocking CD47 antibody suppresses stem cell and EGF signaling in triple-negative breast cancer

(2016) Sukhbir Kaur et al.   Oncotarget

Different Subsets of T Cells, Memory, Effector Functions, and CAR-T Immunotherapy

(2016) Vita Golubovskaya et al.   Cancers

Bioactivity and Safety of IL13R 2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma

(2015) C. E. Brown et al.   CLINICAL CANCER RESEARCH

Phase I Hepatic Immunotherapy for Metastases Study of Intra-Arterial Chimeric Antigen Receptor-Modified T-cell Therapy for CEA+ Liver Metastases

(2015) S. C. Katz et al.   CLINICAL CANCER RESEARCH

Inhibition of CD47 Effectively Targets Pancreatic Cancer Stem Cells via Dual Mechanisms

(2015) M. Cioffi et al.   CLINICAL CANCER RESEARCH

Adoptive therapy with CAR redirected T cells: the challenges in targeting solid tumors

(2015) Hinrich Abken   Immunotherapy

Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated With Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor

(2015) James N. Kochenderfer et al.   JOURNAL OF CLINICAL ONCOLOGY

Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia

(2015) David L. Porter et al.   Science Translational Medicine

Designing CAR T cells for glioblastoma

(2015) Marcela V Maus   OncoImmunology

Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia

(2014) M. L. Davila et al.   Science Translational Medicine

Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity

(2014) P. S. Adusumilli et al.   Science Translational Medicine

CAR T cells: driving the road from the laboratory to the clinic

(2013) Eleanor J. Cheadle et al.   IMMUNOLOGICAL REVIEWS

Thrombospondin-1 is a CD47-dependent endogenous inhibitor of hydrogen sulfide signaling in T cell activation

(2013) Thomas W. Miller et al.   MATRIX BIOLOGY

Intravenous Delivery of siRNA Targeting CD47 Effectively Inhibits Melanoma Tumor Growth and Lung Metastasis

(2013) Yuhua Wang et al.   MOLECULAR THERAPY

Anti-CD47 antibodies promote phagocytosis and inhibit the growth of human myeloma cells

(2012) D Kim et al.   LEUKEMIA

The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors

(2012) S. B. Willingham et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

CD47-signal regulatory protein-  (SIRP ) interactions form a barrier for antibody-mediated tumor cell destruction

(2011) X. W. Zhao et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin Lymphoma

(2010) Mark P. Chao et al.   CELL

Thrombospondin-1 Inhibits VEGF Receptor-2 Signaling by Disrupting Its Association with CD47

(2010) Sukhbir Kaur et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

CD47 Is an Adverse Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem Cells

(2009) Ravindra Majeti et al.   CELL